Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xbrane Biopharma Plans to Continue Phase III Trial of its Xlucane\u00ae (Ranibizumab) Biosimilar Product","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xbrane Has Initiated Development of Two New Biosimilar Candidates, Building an Oncology Biosimilar Portfolio Targeting \u20ac23B in Annual Reference Product Sales","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"SWEDEN","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$88.0 million","upfrontCash":"$8.0 million","newsHeadline":"Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA\u00ae (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stada and Xbrane Obtain British Approval for Ximluci\u00ae (ranibizumab) Biosimilar Referencing Lucentis\u00ae","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Xbrane Biopharma

    Menu

    Xbrane Biopharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Xbrane Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Stada and Xbrane Obtain British Approval for Ximluci® (ranibizumab) Biosimilar Referencing Lucentis®

              Details:

              Ximluci (ranibizumab) binds and inhibits VEGF-A, including VEGF110, preventing the interaction of VEGF-A with VEGFR1 and VEGFR2 on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.

              Lead Product(s): Ranibizumab

              Therapeutic Area: Ophthalmology Product Name: Ximluci

              Highest Development Status: Approved Product Type: Large molecule

              Recipient: STADA Arzneimittel

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 16, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Xbrane Biopharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid ...

              Details:

              Under the terms of the agreement, Biogen will gain exclusive global regulatory, manufacturing, and commercial rights to Xcimzane™ and will be the Marketing Authorization Holder.

              Lead Product(s): Certolizumab Pegol

              Therapeutic Area: Immunology Product Name: Xcimzane

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Biogen

              Deal Size: $88.0 million Upfront Cash: $8.0 million

              Deal Type: Licensing Agreement February 07, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Xbrane Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Xbrane Has Initiated Development of Two New Biosimilar Candidates, Building an Oncology Biosimilar Portfolio Targeting €23B in Annual Reference Product Sales

              Details:

              Company has announced the initiation of developing two new biosimilar candidates referencing Keytruda® and Darzalex® respectively. Together with Xdivane™, these new biosimilar candidates form an oncology biosimilar portfolio.

              Lead Product(s): Pembrolizumab

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 13, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Xbrane Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Xbrane Biopharma Plans to Continue Phase III Trial of its Xlucane® (Ranibizumab) Biosimilar Product

              Details:

              The Xplore trial, which was started in 2019, is intended to study the biosimilarity of Xlucane as compared to Novartis’s Lucentis® in wet age-related macular degeneration (AMD).

              Lead Product(s): Ranibizumab

              Therapeutic Area: Ophthalmology Product Name: Xlucane

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 23, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY